News

Talem Therapeutics has advanced development of candidate panel TATX-112, against an undisclosed target, into formal lead candidate characterization.

23-H7 binds to all tested variants of concern and blocks the RBD/ACE2 binding interaction indirectly through an alternative mechanism of action

Increase in gross profit and expansion in research and development initiatives

The Screening Addresses Potential Approaches to Treating Emerging and Future Variants of SARS-CoV-2 Through Multi-Antibody Combination Therapy

Management to provide update on emerging SARS-CoV-2 variants of concern.

Treatment of Syrian hamsters with a cocktail of four monoclonal antibodies resulted in strong anti-viral effects against SARS-CoV-2